Management of HLA-B27 Associated Uveitis with Genital Lesions

Initial Assessment and Diagnosis

HLA-B27 associated uveitis with genital lesions suggests a possible diagnosis of Behçet's syndrome or another spondyloarthritis with extra-articular manifestations, according to the American College of Rheumatology 1, 2
Genital ulcers in this context may represent mucocutaneous manifestations of an underlying systemic inflammatory condition, as noted by the European League Against Rheumatism 1

The American College of Rheumatology recommends topical glucocorticoids as initial treatment to control ocular inflammation 3, 4
For HLA-B27 associated acute anterior uveitis, topical treatment is often sufficient as it is typically episodic and self-limiting, according to the American Academy of Ophthalmology 5
Monitor patients with controlled uveitis on stable therapy no less frequently than every 3 months, as suggested by the American College of Rheumatology 3
If tapering or discontinuing topical glucocorticoids, ophthalmologic monitoring should occur within one month after each change, as recommended by the American Academy of Ophthalmology 3

Topical steroids should be used for the treatment of genital ulcers, according to the European Academy of Dermatology and Venereology 1
Colchicine should be tried first for prevention of recurrent genital ulcers, as suggested by the European League Against Rheumatism 1
For refractory cases, consider systemic immunosuppressives such as azathioprine, thalidomide, interferon-alpha, TNF-alpha inhibitors, or apremilast, as recommended by the American College of Rheumatology 1

Initial therapy should include topical corticosteroids for uveitis and topical steroids for genital ulcers, with colchicine for prevention of recurrent genital ulcers, as suggested by the American College of Rheumatology 1, 3, 4
For refractory uveitis, progress to systemic immunosuppressive therapy, considering methotrexate as first-line systemic agent, and add monoclonal antibody TNF inhibitors (adalimumab or infliximab) for inadequate response, as recommended by the American Academy of Ophthalmology 1, 3, 4

Patients with controlled uveitis should be monitored every 3 months, as suggested by the American Academy of Ophthalmology 3
When changing topical glucocorticoid therapy, follow up within one month, as recommended by the American Academy of Ophthalmology 3
When changing systemic therapy, ophthalmologic monitoring should occur within two months, as suggested by the American College of Rheumatology 3

Complications of untreated uveitis include posterior synechiae, cataracts, glaucoma, and vision loss, as noted by the American Academy of Ophthalmology 5

Collaboration between ophthalmologists, rheumatologists, and dermatologists is essential for optimal management, as recommended by the European League Against Rheumatism 1
Early detection through regular screening and appropriate treatment can improve outcomes and prevent complications, as suggested by the American Academy of Ophthalmology 5